









Markets
/
Stocks
/
nasdaq-dyai
/

Dyadic International Inc

DYAI

1.070USD

+0.088+9.01%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

32.25MMarket Cap

LossP/E TTM



Dyadic International Inc

1.070

+0.088+9.01%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a . Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

216 / 506

Overall Ranking

346 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

9.000

Target Price

+816.87%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Its lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 19.28% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 3.50M.

Fairly Valued

The company’s latest PE is -5.76, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 14.22M shares, decreasing 0.47% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 860.66K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 7.37, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 966.63K, representing a year-over-year increase of 150.49%, while its net profit experienced a year-over-year increase of 12.29%.

Score

Industry at a Glance

Previous score

7.37

Change



Financials

5.28

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.70

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.60

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.27

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -5.28, which is -0.80% below the recent high of -5.24 and -31.84% above the recent low of -6.96.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 216/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.03. The average price target for Dyadic International Inc is 9.00, with a high of 9.00 and a low of 9.00.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 8.63, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 1.11 and the support level at 0.81, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.63

Change

0.36

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.024

Buy

RSI(14)

65.029

Neutral

STOCH(KDJ)(9,3,3)

70.943

Buy

ATR(14)

0.059

Low Volatility

CCI(14)

215.656

Overbought

Williams %R

10.526

Overbought

TRIX(12,20)

0.432

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

1.002

Buy

MA10

0.989

Buy

MA20

0.954

Buy

MA50

0.956

Buy

MA100

0.987

Buy

MA200

1.242

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 39.41%, representing a quarter-over-quarter decrease of 16.67%. The largest institutional shareholder is The Vanguard, holding a total of 860.66K shares, representing 2.38% of shares outstanding, with 11.94% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Emalfarb (Mark A)

4.73M

Francisco Trust

3.41M

Bandera Partners LLC

1.57M

Chapin Davis Asset Management

842.85K

-2.93%

The Vanguard Group, Inc.

Star Investors

814.34K

+1.06%

Tarnok (Michael P)

281.03K

+3.99%

Geode Capital Management, L.L.C.

258.42K

+7.60%

Northeast Financial Consultants Inc

250.00K

Truist Bank

250.00K

BlackRock Institutional Trust Company, N.A.

246.86K

-0.39%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.15, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.96. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.